Biomea Fusion dosed the first participant in a new arm of its OPAL research study. This trial evaluates the investigational drug icovamenib in combination with the weight-loss drug semaglutide.
The study targets overweight or obese individuals without type 2 diabetes. Researchers aim to determine if the combination enhances weight loss while improving physical function, body composition, and muscle health.
This randomized, double-blind study will enroll 64 participants. The primary endpoint will be assessed at 24 weeks.
This clinical phase follows encouraging preclinical findings. The development marks a strategic move for Biomea Fusion within the competitive obesity treatment market.